Phio Pharmaceuticals (NASDAQ:PHIO) Director Ronald Todd Plott Buys 15,000 Shares of Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Director Ronald Todd Plott acquired 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were bought at an average price of $1.14 per share, with a total value of $17,100.00. Following the completion of the transaction, the director directly owned 15,000 shares in the company, valued at approximately $17,100. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Phio Pharmaceuticals Trading Up 5.2%

Phio Pharmaceuticals stock opened at $1.21 on Friday. Phio Pharmaceuticals Corp. has a 52 week low of $0.81 and a 52 week high of $4.19. The stock has a market cap of $14.06 million, a PE ratio of -0.94 and a beta of 0.82. The stock has a 50-day moving average price of $1.04 and a 200 day moving average price of $1.12.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36). On average, equities analysts predict that Phio Pharmaceuticals Corp. will post -1.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $14.00.

Hedge Funds Weigh In On Phio Pharmaceuticals

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 60.0% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 92,638 shares of the company’s stock after buying an additional 34,732 shares during the period. Geode Capital Management LLC owned approximately 0.86% of Phio Pharmaceuticals worth $97,000 at the end of the most recent reporting period. Institutional investors own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.